Literature DB >> 26056329

Prognostic significance of β1,6-N-acetylglucosaminyltransferase V expression in patients with hepatocellular carcinoma.

Haiou Liu1, Qian Wu2, Yidong Liu2, Weisi Liu2, Weijuan Zhang3, Deng Pan2, Jiejie Xu4.   

Abstract

OBJECTIVE: Alterations to the N-glycans in glycoproteins have been suggested to play important roles in the proliferation, differentiation, invasion and metastasis of hepatocellular carcinoma (HCC). This study aims to evaluate the potential prognostic value of β1,6-N-acetylglucosaminyltransferase V (Mgat5) in hepatocellular carcinoma patients after surgical resection.
METHODS: We retrospectively enrolled 300 patients (156 in the training cohort and 144 in the validation cohort) with hepatocellular carcinoma undergoing hepatectomy at a single institution. Mgat5 intensities were assessed by immunohistochemistry in the specimens of patients. The Kaplan-Meier method was applied to compare survival curves. Cox regression models were used to analyze the impact of prognostic factors on overall survival and recurrence-free survival. The concordance index was calculated to assess predictive accuracy.
RESULTS: Intratumoral Mgat5 expression was significantly higher than non-tumoral tissues (P < 0.001). In both cohorts, elevated Mgat5 expression in tumor tissues positively correlated with vascular invasion and advanced tumor-node-metastasis stage. High Mgat5 expression indicated poor survival (P < 0.001 in the training cohort and P < 0.001 in the validation cohort) and recurrence (P < 0.001 in both cohorts, respectively) in patients with hepatocellular carcinoma, particularly with early-stage disease. Mgat5 expression was identified as an independent adverse prognostic factor for survival and recurrence. The predictive accuracy of tumor-node-metastasis and Barcelona Clinic Liver Cancer prognostic models was improved when Mgat5 expression was added.
CONCLUSION: Mgat5 expression is a potential independent adverse prognostic biomarker for recurrence and survival of patients with hepatocellular carcinoma after hepatectomy.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  hepatocellular carcinoma; overall survival; prognosis biomarker; recurrence-free survival; β1,6-N-acetylglucosaminyltransferase V

Mesh:

Substances:

Year:  2015        PMID: 26056329     DOI: 10.1093/jjco/hyv080

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  4 in total

Review 1.  Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression.

Authors:  María L Bacigalupo; Pablo Carabias; María F Troncoso
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

2.  Loss of Barx1 promotes hepatocellular carcinoma metastasis through up-regulating MGAT5 and MMP9 expression and indicates poor prognosis.

Authors:  Guodong Wang; Jian Liu; Yi Cai; Jie Chen; Wenbing Xie; Xiangqian Kong; Wenjie Huang; Hao Guo; Xiaodi Zhao; Yuanyuan Lu; Lu Niu; Xiaowei Li; Haijia Zhang; Chao Lei; Zhijie Lei; Jipeng Yin; Hao Hu; Fan Yu; Yongzhan Nie; Limin Xia; Kaichun Wu
Journal:  Oncotarget       Date:  2017-05-30

3.  Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.

Authors:  Kiyotaka Kondo; Yoichiro Harada; Miyako Nakano; Takehiro Suzuki; Tomoko Fukushige; Ken Hanzawa; Hirokazu Yagi; Koichi Takagi; Keiko Mizuno; Yasuhide Miyamoto; Naoyuki Taniguchi; Koichi Kato; Takuro Kanekura; Naoshi Dohmae; Kentaro Machida; Ikuro Maruyama; Hiromasa Inoue
Journal:  J Biol Chem       Date:  2022-04-18       Impact factor: 5.486

Review 4.  Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma.

Authors:  Raphaela Menezes de Oliveira; Carlos Andre Ornelas Ricart; Aline Maria Araujo Martins
Journal:  Front Oncol       Date:  2018-01-15       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.